Clinical Trials Sponsored by A2 Biotherapeutics Inc.

Total 188 results

A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

Cancer | Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | NSCLC | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Cancer Metastatic | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | NSCLC, Recurrent | Non Small Cell Lung Cancer Recurrent | Non-Small Cell...

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (BASECAMP-1)

Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Pancreas Cancer | Ovarian Carcinoma | Solid Tumor, Adult | CRC | Mesothelioma; Lung

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Sonoma Biotherapeutics, Inc.

Recruiting

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
D2M Biotherapeutics Inc.

Recruiting

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumor

United States
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis

Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class III

United States
Worg Biotherapeutics Inc.

Recruiting

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

Graves Disease

United States
Perceive Biotherapeutics, Inc.

Recruiting

VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

Australia, Israel
Bolt Biotherapeutics, Inc.

Recruiting

Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Clear Cell Renal Cell Carcinoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, Netherlands, Sweden
Artiva Biotherapeutics, Inc.

Not yet recruiting

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Capsida Biotherapeutics, Inc.

Not yet recruiting

Natural History Study in Pediatric Patients With STXBP1 Encephalopathy With Epilepsy

STXBP1 Encephalopathy With Epilepsy
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
Iovance Biotherapeutics, Inc.

Recruiting

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Cervical Carcinoma

United States, Spain, United Kingdom, Germany, France, Italy, Netherlands, Switzerland
CardioVascular BioTherapeutics, Inc.

Not yet recruiting

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Myocardial Ischemia | Coronary Disease | Coronary Heart Disease | Coronary Arteriosclerosis
Stealth BioTherapeutics Inc.

Active, not recruiting

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) (NuPower)

Mitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial Complex I Deficiency | Mitochondrial Pathology | Mitochondrial DNA Depletion | Mitochondrial DNA Mutation | Mitochondrial DNA Deletion | Mitochondrial Metabolism Defect

Spain, United States, Italy, Netherlands, Australia, Germany, Hungary, New Zealand, Norway, United Kingdom
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-I)

Atopic Dermatitis Eczema

United States, Canada
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Atopic Dermatitis Eczema

United States, Canada
Arcutis Biotherapeutics, Inc.

Completed

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (ARRECTOR)

Scalp Psoriasis

United States, Canada
Stealth BioTherapeutics Inc.

Available

An Intermediate Size Expanded Access Protocol of Elamipretide

Mitochondrial Diseases | Barth Syndrome
Sensei Biotherapeutics, Inc.

Terminated

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
Arcutis Biotherapeutics, Inc.

Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Psoriasis | Plaque Psoriasis

United States, Canada, Dominican Republic
Steminent Biotherapeutics Inc.

Completed

Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee

Osteoarthritis Knee

Taiwan
Arcutis Biotherapeutics, Inc.

Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (MUSE)

Plaque Psoriasis

United States
Stealth BioTherapeutics Inc.

Terminated

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension (MMPOWER-3)

Primary Mitochondrial Myopathy

United States, Germany, Canada, Italy, United Kingdom, Denmark, Hungary
Stealth BioTherapeutics Inc.

Terminated

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Primary Mitochondrial Disease

United States
Sensei Biotherapeutics, Inc.

Withdrawn

SNS-301 Monotherapy in High Risk MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia (CMML)
Stealth BioTherapeutics Inc.

Terminated

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery (EVOLVE)

Renal Artery Obstruction | Ischemia Reperfusion Injury | Hypertension, Renovascular

United States
Stealth BioTherapeutics Inc.

Completed

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Heart Failure

Netherlands, Italy, United Kingdom
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER)

Mitochondrial Myopathy

United States
Prometic Biotherapeutics, Inc.

Completed

A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

Hypoplasminogenemia | Type I Plasminogen Deficiency

United States
Stealth BioTherapeutics Inc.

Completed

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration (SPIOC-101)

Age-related Macular Degeneration | Diabetic Macular Edema

United States
Stealth BioTherapeutics Inc.

Withdrawn

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

Heart Failure

Bulgaria
Garnet BioTherapeutics, Inc.

Completed

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

Scar Formation

United States
Nitric BioTherapeutics, Inc

Terminated

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

Venous Ulcers

United States
Stealth BioTherapeutics Inc.

Completed

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Healthy Volunteers

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
Immorna Biotherapeutics, Inc.

Recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

China
Salubris Biotherapeutics Inc

Recruiting

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
Stealth BioTherapeutics Inc.

Completed

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER)

Barth Syndrome

United States
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
Arcutis Biotherapeutics, Inc.

Active, not recruiting

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)

Atopic Dermatitis Eczema

United States, Canada
Conjupro Biotherapeutics, Inc.

Suspended

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

CD20 Positive Non Hodgkin Lymphoma

United States
Stealth BioTherapeutics Inc.

Completed

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2)

Age-related Macular Degeneration

United States
Iovance Biotherapeutics, Inc.

No longer available

Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

United States
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Atopic Dermatitis Eczema

United States, Canada

Clinical Trials Sponsored by A2 Biotherapeutics Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations